Selective targeting or reprogramming of intra-tumoral Tregs

Area of Science:

• Immunology
• Oncology
• Cancer Immunotherapy

Background:

• Regulatory T cells (Tregs) suppress anti-tumor immunity in the tumor microenvironment.
• Tregs contribute to tumor progression and metastasis by evading immune responses and immunotherapy.
• Intra-tumoral Tregs are clonally distinct from peripheral Tregs and represent a specific therapeutic target.

Purpose of the Study:

• To explore novel strategies for selectively targeting and reprogramming intra-tumoral Tregs.
• To enhance anti-cancer immune responses by destabilizing or depleting tumor-infiltrating Tregs.
• To overcome immune evasion mechanisms employed by Tregs in solid cancers.

Main Methods:

• Investigating transcription factors like Helios and Trps1 that regulate Treg stability.
• Evaluating targeted therapies such as anti-CCR8 and Bempegaldesleukin (IL-2Rβγ agonist) for selective Treg depletion.
• Exploring reprogramming approaches using Blimp-1 inhibitors and glucocorticoid-induced TNFR-related protein agonists.

Main Results:

• Selective targeting of intra-tumoral Tregs can avoid systemic inflammation.
• Reprogramming Tregs into effector T cells can enhance anti-cancer immunity.
• Therapeutic strategies include novel agents and dietary interventions like high-salt and high-trypsin diets.

Conclusions:

• Selective depletion or reprogramming of intra-tumoral Tregs is a promising avenue in cancer immunotherapy.
• Targeting Treg-specific pathways offers a way to disarm tumor-induced immunosuppression.
• Future research focuses on diverting Treg differentiation towards an effector immune profile.